[Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
Hauschild
A
A
Universitäts-Hautklinik, Kiel.
Dummer
R
R
Garbe
C
C
Kaufmann
R
R
Schadendorf
D
D
Soyer
H P
HP
Stadler
R
R
Tilgen
W
W
D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins